Filtered By:
Source: Journal of the American College of Cardiology
This page shows you your search results in order of relevance. This is page number 13.
Order by Relevance | Date
Total 269 results found since Jan 2013.
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin The Randomized, Multicenter ITALIC Trial
ConclusionsRates of bleeding and thrombotic events were not significantly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin responders. (Is There A LIfe for DES After Discontinuation of Clopidogrel [ITALICplus]; NCT01476020)
Source: Journal of the American College of Cardiology - February 23, 2015 Category: Cardiology Source Type: research
Randomized Trial of Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease The CvLPRIT Trial
ConclusionsIn patients presenting for P-PCI with multivessel disease, index admission complete revascularization significantly lowered the rate of the composite primary endpoint at 12 months compared with treating only the IRA. In such patients, inpatient total revascularization may be considered, but larger clinical trials are required to confirm this result and specifically address whether this strategy is associated with improved survival. (Complete Versus Lesion-only Primary PCI Pilot Study [CvLPRIT]; ISRCTN70913605)
Source: Journal of the American College of Cardiology - March 9, 2015 Category: Cardiology Source Type: research
Pre-Frailty and Risk of Cardiovascular Disease in Elderly Men and Women The Pro.V.A. Study
ConclusionsOur findings suggest that pre-frailty, which is potentially reversible, is independently associated with a higher risk of older adults developing CVD. Among the physical domains of pre-frailty, low gait speed seems to be the best predictor of future CVD.
Source: Journal of the American College of Cardiology - March 9, 2015 Category: Cardiology Source Type: research
Prevalence, Impact, and Predictive Value of Detecting Subclinical Coronary and Carotid Atherosclerosis in Asymptomatic Adults The BioImage Study
ConclusionsDetection of subclinical carotid or coronary atherosclerosis improves risk predictions and reclassification compared with conventional risk factors, with comparable results for either modality. Cost-effective analyses are warranted to define the optimal roles of these complementary techniques. (BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population; NCT00738725)
Source: Journal of the American College of Cardiology - March 16, 2015 Category: Cardiology Source Type: research
Is the Long-Term Outcome of PCI or CABG in Insulin-Treated Diabetic Patients Really Worse Than Non-Insulin-Treated Ones?
In a recent issue of the Journal, Dangas et al. (1), after analyzing 1,850 subjects from the FREEDOM (Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals With Diabetes) trial, found that in patients with diabetes and multivessel coronary artery disease, the rate of major adverse cardiovascular events (death, myocardial infarction, or stroke) is higher in patients treated with insulin than it is in those not treated with insulin. Their work is excellent, and the results deserved to be considered given the large number of patients with diabetes and multivessel coronary artery disease who are...
Source: Journal of the American College of Cardiology - March 16, 2015 Category: Cardiology Source Type: research
First-in-Human Transcatheter Tricuspid Valve Repair in a Patient With Severely Regurgitant Tricuspid Valve
ConclusionsTranscatheter tricuspid valve repair could become an effective treatment for high–surgical risk patients who are non-responsive to optimal medical therapy.
Source: Journal of the American College of Cardiology - March 23, 2015 Category: Cardiology Source Type: research
Relationship of Oxidized Phospholipids on Apolipoprotein B-100 to Cardiovascular Outcomes in Patients Treated With Intensive Versus Moderate Atorvastatin Therapy The TNT Trial
ConclusionsElevated OxPL-apoB levels predict secondary MACE in patients with stable CHD, a risk that is mitigated by atorvastatin 80 mg. (A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels [TNT]; NCT00327691)
Source: Journal of the American College of Cardiology - March 30, 2015 Category: Cardiology Source Type: research
Readmissions After Carotid Artery Revascularization in the Medicare Population
ConclusionsAlmost 10% of Medicare patients undergoing carotid revascularization were readmitted within 30 days of discharge. Compared with CEA, CAS was associated with a greater readmission risk. However, hospitals' RSRR did not differ by their proportional CAS use.
Source: Journal of the American College of Cardiology - April 6, 2015 Category: Cardiology Source Type: research
Impact of Type 1 and 2 Diabetes Mellitus on Long-Term Outcomes After CABG ∗
It is well-established both that the prevalence of diabetes mellitus (DM) is rising rapidly in the developed world and that its presence is a significant risk factor for cardiovascular disease and death (1). Over the last decade, it also has become increasingly clear that for patients with diabetes who require coronary artery revascularization, in addition to optimal medical therapy, that the results of coronary artery bypass grafting (CABG) are superior to percutaneous coronary intervention in terms of significant reductions in mortality, myocardial infarction, and the need for repeat interventions but at the cost of a sl...
Source: Journal of the American College of Cardiology - April 20, 2015 Category: Cardiology Source Type: research
Is CABG Superior to DES for Repeat Revascularization in Patients With Isolated Proximal LAD Disease?
We read with great interest the paper by Hannan et al. (1) comparing the clinical outcomes in a large number of patients with isolated proximal left anterior descending (PLAD) coronary artery disease who underwent coronary artery bypass graft (CABG) surgery and percutaneous coronary interventions (PCIs) with drug-eluting stents (DES). They showed that there were no statistically significant differences in mortality or mortality, myocardial infarction (MI), and/or stroke between the CABG and PCI-DES groups, whereas CABG patients had significantly lower repeat revascularization rates.
Source: Journal of the American College of Cardiology - April 20, 2015 Category: Cardiology Source Type: research
Double Antiplatelet Therapy Duration Standardize or Personalize? ∗
The duration of dual antiplatelet therapy is the subject of debate. Prolonged dual antiplatelet therapy may prevent recurrence of thrombotic events, such as stroke or myocardial infarction (MI), caused by either iterative plaque rupture or complications related to previous revascularization, with increased risk of bleeding. Multiple factors have to be integrated: type of stent, clinical presentation, type of dual antiplatelet therapy, coronary lesion complexity, and patient compliance. The current European guidelines (1) recommend 6 months’ dual antiplatelet therapy in stable patients with coronary artery disease underg...
Source: Journal of the American College of Cardiology - May 18, 2015 Category: Cardiology Source Type: research
Retrograde Recanalization of Chronic Total Occlusions in Europe Procedural, In-Hospital, and Long-Term Outcomes From the Multicenter ERCTO Registry
BackgroundA retrograde approach improves the success rate of percutaneous coronary interventions (PCIs) for chronic total occlusions (CTOs).ObjectivesThe authors describe the European experience with and outcomes of retrograde PCI revascularization for coronary CTOs.MethodsFollow-up data were collected from 1,395 patients with 1,582 CTO lesions enrolled between January 2008 and December 2012 for retrograde CTO PCI at 44 European centers. Major adverse cardiac and cerebrovascular events were defined as the composite of cardiac death, myocardial infarction, stroke, and further revascularization.ResultsThe mean patient age wa...
Source: Journal of the American College of Cardiology - June 1, 2015 Category: Cardiology Source Type: research
Atrial Fibrillation and Renal Function How High Is the Price of Anticoagulation? ∗
For over a half century, vitamin K antagonists, chiefly warfarin, were the exclusive oral anticoagulants available for long-term anticoagulation. Being “the only game in town,” the emphasis of the accompanying clinical research was focused on determining the most appropriate method to measure anticoagulant effects, define the most efficacious and safe target range for anticoagulation, and identify strategies to maintain and reverse therapeutic anticoagulation. This emphasis came at the expense of turning a blind eye to rare concerns raised about the potential for warfarin to cause or worsen renal dysfunction (1,2). Th...
Source: Journal of the American College of Cardiology - June 8, 2015 Category: Cardiology Source Type: research
Left Atrial Appendage Closure to Reduce the Risk of Thromboembolic Complications in Atrial Fibrillation Pay Now and Possibly Pay Later? ∗
Atrial fibrillation (AF) is the most common sustained arrhythmia and currently afflicts 5 million Americans (1). The treatment of AF and its complications costs the United States healthcare system $26 billion annually (2). Due to aging of the population and an increasing incidence of AF risk factors, by the year 2050,>12 million Americans will have this arrhythmia (2). Thromboembolism and its associated morbidity and mortality is the most dreaded complication of AF, and AF has been implicated in up to one quarter of all strokes in patients>80 years of age (2). Anticoagulation has been shown to reduce the risk of AF-associ...
Source: Journal of the American College of Cardiology - June 15, 2015 Category: Cardiology Source Type: research
Reply Mode of Death Prevention by Serelaxin
We thank Dr. Henry and colleagues for their interest in our study on the mode of death in the RELAX-AHF (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure) study of serelaxin in acute heart failure (1). The authors provide very interesting data from their own laboratory on the possible role of serelaxin in modulating cardiac fibrosis, myocyte hypertrophy, and cardiac conduction (2) and speculate that these mechanisms may be potential explanations for the reduction in sudden death and fatal stroke observed with serelaxin treatment in the RELAX-AHF study.
Source: Journal of the American College of Cardiology - June 29, 2015 Category: Cardiology Source Type: research
